Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 6/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686184 | 0.92 | ACACB (0.35) | CMA1ACACBACACA | |
| SCHEMBL2318315 | 0.92 | CTSG (0.32) | CMA1KCNH2ACACBACACACTSG | |
| SCHEMBL2314667 | 0.91 | CTSG (0.32) | CMA1KCNH2ACACBACACACTSG | |
| SCHEMBL3686129 | 0.87 | NPC1 (0.31) | CMA1ACACAGAA | |
| SCHEMBL3687513 | 0.79 | CMA1 (0.38) | CMA1ITGB2ICAM1ITGALCTSG | |
| SCHEMBL3699071 | 0.78 | CMA1 (0.45) | CMA1CTSG | |
| SCHEMBL3699074 | 0.78 | CMA1 (0.45) | CMA1CTSG | |
| Bicarbonate SCHEMBL13822751 | 0.78 | ALDH1A1 (0.42) | GAA | |
| SCHEMBL3695212 | 0.78 | CMA1 (0.35) | CMA1ITGB2ICAM1ITGALMGAM | |
| SCHEMBL3683080 | 0.78 | CMA1 (0.35) | CMA1ITGB2ICAM1ITGALMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | claimed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8377949-B2 | Quinazolinedione chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2188277-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023655-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | CMA1, CTSC, TPSG1 | CMA1 1/4885KCNH2 4304/4885ACACB 161/4885 |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | CMA1 3023/4885KCNH2 2889/4885ACACB 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.